Cargando…
Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States
BACKGROUND: Asthma is the most common inflammatory lung disease in the United States. Since 2015, biologic therapies have provided targeted treatment for patients with severe asthma. OBJECTIVE: To evaluate the trends for in-hospital outcomes of asthma before (2012-2014) and after (2016-2018) the int...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388017/ https://www.ncbi.nlm.nih.gov/pubmed/37404074 http://dx.doi.org/10.18553/jmcp.2023.29.7.721 |
_version_ | 1785082015814516736 |
---|---|
author | Kang, Hye-Rim Hernandez-Con, Pilar Heo, Ji Haeng Wilson, Debbie L Blake, Kathryn V Lang, Jason E Park, Haesuk |
author_facet | Kang, Hye-Rim Hernandez-Con, Pilar Heo, Ji Haeng Wilson, Debbie L Blake, Kathryn V Lang, Jason E Park, Haesuk |
author_sort | Kang, Hye-Rim |
collection | PubMed |
description | BACKGROUND: Asthma is the most common inflammatory lung disease in the United States. Since 2015, biologic therapies have provided targeted treatment for patients with severe asthma. OBJECTIVE: To evaluate the trends for in-hospital outcomes of asthma before (2012-2014) and after (2016-2018) the introduction of biologic therapies for asthma. METHODS: We conducted a nationwide cross-sectional analysis of patients aged 2 years or older who were hospitalized for asthma between 2012 and 2018 using data from the Nationwide Readmissions Database. Outcomes included rates of asthma hospital admission and asthma-related 30-day readmission, hospital length of stay, hospital costs, and inpatient mortality. Generalized linear models assessed trends in rates of asthma admission and readmission, length of stay, costs, and mortality quarterly during 2012-2014 and 2016-2018. RESULTS: Among 691,537 asthma-related admissions, quarterly asthma admission rates significantly decreased (−0.90%, 95% CI = −1.46% to − 0.34%; P = 0.002) during 2016-2018, mainly among adults, but not during 2012-2014. Quarterly assessed readmission rates decreased by 2.40% (−2.85% to −1.96%; P < 0.0001) during 2012-2014 and by 2.12% (−2.74% to − 1.50%; P < 0.0001) during 2016-2018. Mean length of stay for asthma admissions decreased quarterly by 0.44% (−0.49% to − 0.38%; P < 0.0001) during 2012-2014 and by 0.27% (−0.34% to − 0.20%; P < 0.0001) during 2016-2018. Quarterly hospital costs for admissions were unchanged during 2012-2014 but increased by 0.28% (0.21% to 0.35%; P < 0.0001) during 2016-2018. There were no significant trends in inpatient mortality during 2012-2014 and 2016-2018. CONCLUSIONS: After the introduction of new biologics for severe asthma in 2015, asthma-related hospital admissions decreased significantly, whereas hospital costs increased. Asthma-related 30-day readmission rates and length of stay for asthma admissions continuously decreased, whereas inpatient mortality rates remained stable. |
format | Online Article Text |
id | pubmed-10388017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-103880172023-07-31 Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States Kang, Hye-Rim Hernandez-Con, Pilar Heo, Ji Haeng Wilson, Debbie L Blake, Kathryn V Lang, Jason E Park, Haesuk J Manag Care Spec Pharm Research BACKGROUND: Asthma is the most common inflammatory lung disease in the United States. Since 2015, biologic therapies have provided targeted treatment for patients with severe asthma. OBJECTIVE: To evaluate the trends for in-hospital outcomes of asthma before (2012-2014) and after (2016-2018) the introduction of biologic therapies for asthma. METHODS: We conducted a nationwide cross-sectional analysis of patients aged 2 years or older who were hospitalized for asthma between 2012 and 2018 using data from the Nationwide Readmissions Database. Outcomes included rates of asthma hospital admission and asthma-related 30-day readmission, hospital length of stay, hospital costs, and inpatient mortality. Generalized linear models assessed trends in rates of asthma admission and readmission, length of stay, costs, and mortality quarterly during 2012-2014 and 2016-2018. RESULTS: Among 691,537 asthma-related admissions, quarterly asthma admission rates significantly decreased (−0.90%, 95% CI = −1.46% to − 0.34%; P = 0.002) during 2016-2018, mainly among adults, but not during 2012-2014. Quarterly assessed readmission rates decreased by 2.40% (−2.85% to −1.96%; P < 0.0001) during 2012-2014 and by 2.12% (−2.74% to − 1.50%; P < 0.0001) during 2016-2018. Mean length of stay for asthma admissions decreased quarterly by 0.44% (−0.49% to − 0.38%; P < 0.0001) during 2012-2014 and by 0.27% (−0.34% to − 0.20%; P < 0.0001) during 2016-2018. Quarterly hospital costs for admissions were unchanged during 2012-2014 but increased by 0.28% (0.21% to 0.35%; P < 0.0001) during 2016-2018. There were no significant trends in inpatient mortality during 2012-2014 and 2016-2018. CONCLUSIONS: After the introduction of new biologics for severe asthma in 2015, asthma-related hospital admissions decreased significantly, whereas hospital costs increased. Asthma-related 30-day readmission rates and length of stay for asthma admissions continuously decreased, whereas inpatient mortality rates remained stable. Academy of Managed Care Pharmacy 2023-07 /pmc/articles/PMC10388017/ /pubmed/37404074 http://dx.doi.org/10.18553/jmcp.2023.29.7.721 Text en Copyright © 2023, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Kang, Hye-Rim Hernandez-Con, Pilar Heo, Ji Haeng Wilson, Debbie L Blake, Kathryn V Lang, Jason E Park, Haesuk Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States |
title | Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States |
title_full | Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States |
title_fullStr | Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States |
title_full_unstemmed | Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States |
title_short | Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States |
title_sort | nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: a cross-sectional study in the united states |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388017/ https://www.ncbi.nlm.nih.gov/pubmed/37404074 http://dx.doi.org/10.18553/jmcp.2023.29.7.721 |
work_keys_str_mv | AT kanghyerim nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates AT hernandezconpilar nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates AT heojihaeng nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates AT wilsondebbiel nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates AT blakekathrynv nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates AT langjasone nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates AT parkhaesuk nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates |